Phase I dose escalation and expansion study of defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment-refractory pancreatic cancer.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrea wang-gillam, Kian-Huat Lim, Robert R. McWilliams, Rama Suresh, A. Craig Lockhart, Amberly Brown, John Herndon, Katrina Sophia Pedersen, Benjamin R. Tan, Nicolas Boice, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett Herzog, David G. DeNardo
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4286295646